Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Insulin Lispro (Humalog) injectable bulk supplier for pharma manufacturers

Insulin Lispro (Humalog) Injectable U-100, U-200 Suppliers & Bulk Manufacturers

Available Forms: Vials/pens

Available Strengths: U-100, U-200

Reference Brands: Humalog, Admelog, Fiasp(US); Humalog, Fiasp(EU)

Category: Diabetes

Insulin Lispro (Humalog) is a rapid-acting insulin that quickly mimics natural insulin release post-meal. It lowers blood sugar rapidly, providing flexible dosing around mealtimes. Benefits include quick onset, precise glucose control, reduced post-meal hyperglycemia, and improved convenience for insulin therapy, essential for effective management of diabetes.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Insulin Lispro (Humalog) is a rapid-acting insulin approved in the EU and US for post-meal blood glucose control. In the EU, Novo Nordisk’s Fiasp, a faster-acting version, is regulated by EMA with dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, the FDA has approved Humalog and biosimilars like Admelog based on comprehensive clinical data, biosimilarity, and ongoing pharmacovigilance. Both regions require detailed regulatory dossiers for approval and post-marketing safety monitoring. For expert assistance with pharmaceutical dossiers and compliance, visit PharmaTradz, your trusted partner in regulatory solutions.

Insulin Lispro (Humalog) Injectable — third party manufacturing & bulk supply

Insulin Lispro (Humalog) Injectable U-100, U-200 is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Indicative minimum order quantity

Insulin Lispro (Humalog) Injectable is supplied as Vials/pens — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Insulin Lispro (Humalog) Injectable listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Insulin Lispro (Humalog) Injectable →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Insulin Lispro is used to improve blood sugar control in adults and children with diabetes mellitus, including both type 1 and type 2 diabetes. It is a rapid-acting insulin that helps to manage blood glucose levels after meals.

Insulin Lispro is a recombinant human insulin analogue produced using recombinant DNA technology in Escherichia coli bacteria. It differs from human insulin by the reversal of two amino acids—proline and lysine—at positions 28 and 29 on the B-chain, which allows it to act faster in the body.

The trade name for Insulin Lispro is Humalog.

Insulin Lispro (Humalog) is manufactured by Eli Lilly and Company.

The generic name of this product is Insulin Lispro.

The brand name of Insulin Lispro is Humalog.

Insulin Lispro is manufactured by Eli Lilly and Company, with production facilities located in the United States and several other countries, including France and Italy, depending on the regional supply chain.

Related Products

Repaglinide

Strength:
0.5 mg, 1 mg, 2 mg

Form: Tablets

Reference Brands: Prandin (USA)

View Details
Pioglitazone Hydrochloride 150Mg Tablet

Strength:
15 mg, 30 mg, 45 mg

Form: Tablets

Reference Brands: Actos (USA)

View Details
Nateglinide

Strength:
60 mg, 120 mg, 180 mg

Form: Tablets

Reference Brands: Starlix (USA)

View Details
Miglitol

Strength:
25 mg, 50 mg, 100 mg

Form: Tablets

Reference Brands: Glyset (USA), Diastabol (EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.